but decided that Vasant Narasimhan, known as Vas, was the best candidate to take the company forward. Jimenez joined Novartis from a commercial role at Heinz with no experience in the pharma ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

When Vas Narasimhan started as the new CEO of the Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling ...

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested in one, according to its chief executive Vasant Narasimhan.

The Ethos Foundation recommends that shareholders vote against all compensation-related items at the Annual General Meeting on March 7.

Novartis (NVS) CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if its main focus remains on therapeutic areas where it ...

But while "it's a bigger mouthful than expected", the purchase is consistent with Novartis CEO Vasant Narasimhan's plan to invest in innovative drugs with a clear medical need. Don't miss the ...

Novartis’ position about this year’s price increase has been announced during the Q2 2018 earnings call transmitted as a live audio webcast. Vasant Narasimhan, Novartis’ CEO, addressed ...

The Ethos Foundation recommends that Novartis shareholders vote against all compensation-related items at the Basel-based pharmaceutical giant's Annual General Meeting on March 7. In 2024, the ...